Infections  ||| S:0 E:11 ||| NNS
in  ||| S:11 E:14 ||| IN
the  ||| S:14 E:18 ||| DT
immunocompromised  ||| S:18 E:36 ||| JJ
host ||| S:36 E:40 ||| NN
:  ||| S:40 E:42 ||| :
role  ||| S:42 E:47 ||| NN
of  ||| S:47 E:50 ||| IN
daptomycin  ||| S:50 E:61 ||| JJ
Infections  ||| S:61 E:72 ||| NNS
in  ||| S:72 E:75 ||| IN
immunocompromised  ||| S:75 E:93 ||| JJ
host  ||| S:93 E:98 ||| NN
are  ||| S:98 E:102 ||| VBP
increasing  ||| S:102 E:113 ||| VBG
worldwide ||| S:113 E:122 ||| NNS
.  ||| S:122 E:124 ||| .
Definition  ||| S:124 E:135 ||| NN
of  ||| S:135 E:138 ||| IN
immunocompromised  ||| S:138 E:156 ||| JJ
host  ||| S:156 E:161 ||| NN
encompasses  ||| S:161 E:173 ||| VBD
a  ||| S:173 E:175 ||| DT
number  ||| S:175 E:182 ||| NN
of  ||| S:182 E:185 ||| IN
different  ||| S:185 E:195 ||| JJ
pathologies ||| S:195 E:206 ||| NN
,  ||| S:206 E:208 ||| ,
such  ||| S:208 E:213 ||| JJ
as  ||| S:213 E:216 ||| IN
immune-haematological ||| S:216 E:237 ||| NNP
,  ||| S:237 E:239 ||| ,
oncological ||| S:239 E:250 ||| NN
,  ||| S:250 E:252 ||| ,
intensivist ||| S:252 E:263 ||| NN
,  ||| S:263 E:265 ||| ,
in  ||| S:265 E:268 ||| IN
addition  ||| S:268 E:277 ||| NN
to  ||| S:277 E:280 ||| TO
all  ||| S:280 E:284 ||| DT
patients  ||| S:284 E:293 ||| NNS
being  ||| S:293 E:299 ||| VBG
treated  ||| S:299 E:307 ||| VBN
with  ||| S:307 E:312 ||| IN
different  ||| S:312 E:322 ||| JJ
monoclonal  ||| S:322 E:333 ||| JJ
antibodies  ||| S:333 E:344 ||| NNS
and  ||| S:344 E:348 ||| CC
TNF-alfa  ||| S:348 E:357 ||| JJ
inhibitors ||| S:357 E:367 ||| NN
.  ||| S:367 E:369 ||| .
Daptomycin  ||| S:369 E:380 ||| NNP
is  ||| S:380 E:383 ||| VBZ
a  ||| S:383 E:385 ||| DT
novel  ||| S:385 E:391 ||| NN
lipopeptide  ||| S:391 E:403 ||| VBZ
antimicrobial  ||| S:403 E:417 ||| JJ
drug ||| S:417 E:421 ||| NN
,  ||| S:421 E:423 ||| ,
its  ||| S:423 E:427 ||| PRP$
activity  ||| S:427 E:436 ||| NN
against  ||| S:436 E:444 ||| IN
Gram-positive  ||| S:444 E:458 ||| JJ
bacteria  ||| S:458 E:467 ||| NNS
being  ||| S:467 E:473 ||| VBG
rapidly  ||| S:473 E:481 ||| RB
cidal ||| S:481 E:486 ||| JJ
,  ||| S:486 E:488 ||| ,
without  ||| S:488 E:496 ||| IN
phenomenon  ||| S:496 E:507 ||| NN
related  ||| S:507 E:515 ||| VBN
to  ||| S:515 E:518 ||| TO
bacterial  ||| S:518 E:528 ||| JJ
lysis ||| S:528 E:533 ||| NN
.  ||| S:533 E:535 ||| .
Daptmomycin  ||| S:535 E:547 ||| NNP
received  ||| S:547 E:556 ||| VBD
approval  ||| S:556 E:565 ||| NN
for  ||| S:565 E:569 ||| IN
treatment  ||| S:569 E:579 ||| NN
of  ||| S:579 E:582 ||| IN
complicated  ||| S:582 E:594 ||| JJ
skin  ||| S:594 E:599 ||| NN
and  ||| S:599 E:603 ||| CC
skin  ||| S:603 E:608 ||| NN
structures  ||| S:608 E:619 ||| NNS
infections ||| S:619 E:629 ||| NNS
,  ||| S:629 E:631 ||| ,
sepsis ||| S:631 E:637 ||| NN
,  ||| S:637 E:639 ||| ,
and  ||| S:639 E:643 ||| CC
right  ||| S:643 E:649 ||| JJ
side  ||| S:649 E:654 ||| NN
endocarditis  ||| S:654 E:667 ||| VBZ
sustained  ||| S:667 E:677 ||| VBN
by  ||| S:677 E:680 ||| IN
S.  ||| S:680 E:683 ||| NNP
aureus ||| S:683 E:689 ||| NN
.  ||| S:689 E:691 ||| .
This  ||| S:691 E:696 ||| DT
article  ||| S:696 E:704 ||| NN
will  ||| S:704 E:709 ||| MD
focus  ||| S:709 E:715 ||| VB
the  ||| S:715 E:719 ||| DT
role  ||| S:719 E:724 ||| NN
of  ||| S:724 E:727 ||| IN
this  ||| S:727 E:732 ||| DT
new  ||| S:732 E:736 ||| JJ
drug  ||| S:736 E:741 ||| NN
in  ||| S:741 E:744 ||| IN
the  ||| S:744 E:748 ||| DT
treatment  ||| S:748 E:758 ||| NN
of  ||| S:758 E:761 ||| IN
severe  ||| S:761 E:768 ||| JJ
infections  ||| S:768 E:779 ||| NNS
in  ||| S:779 E:782 ||| IN
the  ||| S:782 E:786 ||| DT
immunocompromised  ||| S:786 E:804 ||| JJ
host ||| S:804 E:808 ||| NN
.  ||| S:808 E:810 ||| .
Clinical  ||| S:810 E:819 ||| JJ
cases  ||| S:819 E:825 ||| NNS
observed  ||| S:825 E:834 ||| VBD
recently  ||| S:834 E:843 ||| RB
will  ||| S:843 E:848 ||| MD
be  ||| S:848 E:851 ||| VB
also  ||| S:851 E:856 ||| RB
presented ||| S:856 E:865 ||| VBN
.  ||| S:865 E:867 ||| .
